IVA
Price
$2.24
Change
-$0.01 (-0.44%)
Updated
Sep 13 closing price
9 days until earnings call
MRNA
Price
$69.39
Change
+$1.11 (+1.63%)
Updated
Sep 16, 11:57 AM (EDT)
45 days until earnings call
Ad is loading...

IVA vs MRNA

Header iconIVA vs MRNA Comparison
Open Charts IVA vs MRNABanner chart's image
Inventiva SA
Price$2.24
Change-$0.01 (-0.44%)
Volume$2.7K
CapitalizationN/A
Moderna
Price$69.39
Change+$1.11 (+1.63%)
Volume$1.82K
CapitalizationN/A
View a ticker or compare two or three
IVA vs MRNA Comparison Chart
Loading...
MRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
IVA vs. MRNA commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVA is a Hold and MRNA is a Hold.

COMPARISON
Comparison
Sep 16, 2024
Stock price -- (IVA: $2.24 vs. MRNA: $68.28)
Brand notoriety: IVA: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IVA: 34% vs. MRNA: 269%
Market capitalization -- IVA: $121.23M vs. MRNA: $26.25B
IVA [@Biotechnology] is valued at $121.23M. MRNA’s [@Biotechnology] market capitalization is $26.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $606.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IVA’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • IVA’s FA Score: 0 green, 5 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, MRNA is a better buy in the long-term than IVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRNA’s TA Score shows that 4 TA indicator(s) are bullish.

  • MRNA’s TA Score: 4 bullish, 4 bearish.

Price Growth

IVA (@Biotechnology) experienced а +1.82% price change this week, while MRNA (@Biotechnology) price change was -6.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.56%. For the same industry, the average monthly price growth was +4.67%, and the average quarterly price growth was -1.44%.

Reported Earning Dates

IVA is expected to report earnings on Nov 21, 2024.

MRNA is expected to report earnings on Oct 31, 2024.

Industries' Descriptions

@Biotechnology (+2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($26.2B) has a higher market cap than IVA($121M). MRNA YTD gains are higher at: -31.342 vs. IVA (-50.399).
IVAMRNAIVA / MRNA
Capitalization121M26.2B0%
EBITDAN/A-3.78B-
Gain YTD-50.399-31.342161%
P/E RatioN/AN/A-
RevenueN/A4.99B-
Total CashN/A8.49B-
Total DebtN/A1.27B-
TECHNICAL ANALYSIS
Technical Analysis
MRNA
RSI
ODDS (%)
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bearish Trend 4 days ago
81%
MACD
ODDS (%)
Bullish Trend 4 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
83%
View a ticker or compare two or three
Ad is loading...
MRNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DMGGF0.370.02
+6.85%
DMG Blockchain Solutions Inc.
CSCCF6.760.19
+2.94%
CAPSTONE COPPER CORP.
ASHTY282.143.21
+1.15%
Ashtead Group PLC
BVVBY66.560.48
+0.73%
Bureau Veritas SA
GICCX13.120.08
+0.61%
Goldman Sachs Intl Sm Cp Insghts C

IVA and

Correlation & Price change

A.I.dvisor tells us that IVA and THAR have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IVA and THAR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IVA
1D Price
Change %
IVA100%
-0.44%
THAR - IVA
24%
Poorly correlated
-0.67%
OCGN - IVA
24%
Poorly correlated
+0.83%
IMMP - IVA
23%
Poorly correlated
+0.38%
MRNA - IVA
23%
Poorly correlated
-2.01%
NVCT - IVA
23%
Poorly correlated
+2.62%
More